Bayer’s new symptomatic chronic heart failure treatment Verquvo (vericiguat) approved in EU


21 July 2021 - Approved for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy.

The European Commission has granted marketing authorisation in the European Union for vericiguat under the brand name Verquvo.

Read Bayer press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe